Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Nuclear Medicine

• Publication date

  2001-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 11337531
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Complete ablation of small squamous cell carcinoma xenografts with186Re-labeled monoclonal antibody E48

  2007cited by this paper
• Immunoreactivity of monoclonal anti-melanoma antibodies in relation to the amount of radioactive iodine substituted to the antibody molecule

  2004cited by this paper
• Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer.

  2000cited by this paper
• 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study.

  1999cited by this paper
• 131 I Radioconjugated Antibodies for the Locoregional Radioimmunotherapy of High-grade Malignant Glioma

  1999cited by this paper
• Chloramine-T in high-specific-activity radioiodination of antibodies using N-succinimidyl-3-(trimethylstannyl)benzoate as an intermediate.

  1998cited by this paper
• Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.

  1998cited by this paper
• All of the above (with caveats for each).

  1998cited by this paper
• Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.

  1997cited by this paper
• High dose rhenium‐186‐labeling of monoclonal antibodies for clinical application

  1997cited by this paper
• Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

  1995cited by this paper
• Review of a four-year experience iodinating monoclonal antibodies with therapeutic amounts of I-131

  1995cited by this paper
• [125I]IgM (KAU) human monoclonal cold agglutinin: labelling and studies on its biological activity.

  1995cited by this paper
• Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity.

  1995cited by this paper
• Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.

  1995cited by this paper
• Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer.

  1995cited by this paper
• Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue.

  1995cited by this paper
• The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels.

  1994cited by this paper
• Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.

  1994cited by this paper
• Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol.

  1993cited by this paper
• Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients.

  1993cited by this paper
• Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.

  1992cited by this paper
• Expression and characterization of two differentiation antigens in human stratified squamous epithelia and carcinomas

  1992cited by this paper
• Comparison of 131I‐labelled anti‐episialin 139H2 with cisplatin, cyclophosphamide or external‐beam radiation for anti‐tumor efficacy in human ovarian cancer xenografts

  1992cited by this paper
• Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125.

  1992cited by this paper
• Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.

  1992cited by this paper
• Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein.

  1991cited by this paper
• Folate-binding protein is a marker for ovarian cancer.

  1991cited by this paper
• Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation.

  1990cited by this paper
• Evaluation of a remote radioiodination system for radioimmunotherapy.

  1990influential reference
• Production of monoclonal antibodies to squamous cell carcinoma antigens.

  1990cited by this paper
• Imaging and treatment of B-cell lymphoma.

  1990cited by this paper
• Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer.

  1989cited by this paper
• Iodination of monoclonal IgG antibodies at a sub-stoichiometric level: immunoreactivity changes related to the site of iodine incorporation.

  1987cited by this paper
• In vitro measurement of avidity of radioiodinated antibodies.

  1987cited by this paper
• An improved Iodogen method of labelling antibodies with 123I

  1986cited by this paper
• Iodination of monoclonal antibodies for diagnosis and radiotherapy using a convenient one vial method.

  1986cited by this paper
• Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1.1 monoclonal antibody.

  1985cited by this paper
• High-level iodination of monoclonal antibody fragments for radiotherapy.

  1984cited by this paper
• Protein iodination using Iodogen.

  1983cited by this paper
• Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

  1978cited by this paper

• Standard Radio-Iodine Labeling Protocols Impaired the Functional Integrity of Mesenchymal Stem/Stromal Cell Exosomes

  2024cites this paper
• Future Prospective of Radiopharmaceuticals from Natural Compounds Using Iodine Radioisotopes as Theranostic Agents

  2022cites this paper
• ImmunoPET: Concept, Design, and Applications.

  2020cites this paper
• Basic and practical concepts of radiopharmaceutical purification methods.

  2019cites this paper
• Radiobromine and radioiodine for medical applications

  2019cites this paper
• Immunoglobulins as Radiopharmaceutical Vectors

  2019cites this paper
• Treatment of Hepatocellular Carcinoma by Intratumoral Injection of 125I-AA98 mAb and Its Efficacy Assessments by Molecular Imaging

  2019cites this paper
• SPECT imaging and radionuclide therapy of glioma using 131I labeled Buthus martensii Karsch chlorotoxin

  2017cites this paper
• Bioengineered Magnetoferritin Nanoprobes for Single-Dose Nuclear-Magnetic Resonance Tumor Imaging.

  2016cites this paper
• Preparation and preclinical evaluation of 131 I-trastuzumab for breast cancer.

  2016cites this paper
• (125)I-Tetrazines and Inverse-Electron-Demand Diels-Alder Chemistry: A Convenient Radioiodination Strategy for Biomolecule Labeling, Screening, and Biodistribution Studies.

  2016cites this paper
• A pioneer experience in Malaysia on In-house Radio-labelling of (131)I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose (131)I-rituximab-BEAM conditioning autologous transplant.

  2016cites this paper
• (131)I-Nimotuzumab - A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR.

  2015cites this paper
• The ultimate radiochemical nightmare: upon radio-iodination of Botulinum neurotoxin A, the introduced iodine atom itself seems to be fatal for the bioactivity of this macromolecule

  2015influential citation
• Comparison of Succinimidyl [125I]Iodobenzoate with Iodogen Iodination Methods to Study Pharmacokinetics and ADME of Biotherapeutics

  2014cites this paper
• Clinical scale preparation and evaluation of 131I-Rituximab for Non-Hodgkin's Lymphoma

  2014cites this paper
• Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling.

  2014cites this paper
• Phase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients

  2013cites this paper
• Treatment of Lymphoma with 131I-Chimeric Monoclonal Antibodies

  2012cites this paper
• Diagnostic Imaging Agents

  2012cites this paper
• Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion

  2012cites this paper
• Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD.

  2012cites this paper
• Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritis.

  2011cites this paper
• Synthesis of phosphine and antibody-azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach.

  2011cites this paper
• Three spectroscopic techniques evaluated as a tool to study the effects of iodination of monoclonal antibodies, exemplified by rituximab.

  2011cites this paper
• A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth

  2011cites this paper
• A Simple and Safe Method for 131I Radiolabeling of Rituximab for Myeloablative High-Dose Radioimmunotherapy

  2009cites this paper
• In-Line Radiolabeling: A Novel Continuous-Flow System for Commercial-Scale Protein Labeling

  2009cites this paper
• Identification of Inflamed Atherosclerotic Plaque using 123I-Labeled Interleukin-2 Scintigraphy in High-Risk Peritoneal Dialysis Patients: A Pilot Study

  2009cites this paper
• The preparation of radiolabeled monoclonal antibodies for human use

  2009cites this paper
• 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy

  2009cites this paper
• Choice of Radionuclides and Radiolabelling Techniques

  2008cites this paper
• A prospective study of macrophage migration inhibitory factor as a marker of inflammatory detection

  2008cites this paper
• Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

  2008cites this paper
• Biodegradation of 125I-Labeled monoclonal antibodies after intravenous administration to rats with experimental C6 glioma

  2008cites this paper
• Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30

  2008cites this paper
• Targeted Radionuclide Tumor Therapy

  2008cites this paper
• NOUVEAUX RADIOTRACEURS PEPTIDIQUES POUR L'IMAGERIE NUCLEAIRE Radiomarquage, evaluations physico-chimiques et pharmacologiques

  2008cites this paper
• Radioiodine Labeled Anti-MIF McAb: A Potential Agent for Inflammation Imaging

  2007cites this paper
• An electrochemical method to detect folate receptor positive tumor cells

  2007cites this paper
• Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models

  2007cites this paper
• Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

  2006cites this paper
• Role of folate receptor genes in reproduction and related cancers.

  2006cites this paper
• Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo.

  2006cites this paper
• (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.

  2005cites this paper
• Pharmacokinetics, Biodistribution, and Radioimmunotherapy with Monoclonal Antibody 776.1 in a Murine Model of Human Ovarian Cancer

  2005cites this paper
• Radiotherapy of Human Xenograft NSCLC Tumors in Nude Mice with a 90Y-Labeled Anti-Tissue Factor Antibody

  2005cites this paper
• Modulation of Folate Receptor-alpha by Glucocorticoid Receptor and Progesterone Receptor

  2005cites this paper
• Manufacturing I-123-labelled radiopharmaceuticals. Pitfalls and solutions

  2005cites this paper
• Activated vitronectin as a target for anticancer therapy with human antibodies

  2004cites this paper
• 131I-rituximab: relationship between immunoreactivity and specific activity.

  2004cites this paper
• Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy.

  2004cites this paper
• High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy

  2004cites this paper
• 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.

  2003cites this paper
• Receptor induction and targeted drug delivery: a new antileukaemia strategy

  2003cites this paper
• Long-Lived Positron Emitters Zirconium-89 and Iodine-124 for Scouting of Therapeutic Radioimmunoconjugates with PET

  2003cites this paper
• Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects.

  2003cites this paper